On February 23, 2015, Nature’s Way received a letter which constituted “a request for documents and information relating to an ongoing investigation by the New York State Office of the Attorney General (“NYAG”) concerning the authenticity and purity of herbal dietary supplements and associated marketing.” The letter from the NYAG makes no allegations against Nature’s Way and provides no indications of any quality or compliance problem with any Nature’s Way product. The letter is simply a “request” for documents and information.
Nature’s Way products are produced in accordance with the federal Food and Drug Administration’s (FDA’s) Dietary Supplement Good Manufacturing Practices (GMPs), 21 CFR 111. Nature’s Way is audited by FDA to confirm compliance and continues to hold Dietary Supplement GMP Certification through NSF International, a GMP Certificate from the Australian Department of Health’s Therapeutic Goods Association (TGA) and is a licensed site for the production of Natural Health Products (NHPs) marketed in Canada. Nature’s Way intends to cooperate with the NYAG request for documents and information, as we are proud of our Quality Assurance processes and the steps that we take to both comply with the law and produce products of the highest quality.
For Immediate Release:
Remifemin® Black Cohosh Found Safe for Reducing Menopause Symptoms in Postmenopausal Women
Research Published in Cancer Epidemiology Biomarkers & Prevention, August 2009
BOSTON, MA, SEPTEMBER 23, 2009 — Natural Products Expo East 2009 —
Many women are choosing dietary supplements for the management of menopausal symptoms – especially since serious health concerns have been raised about hormone replacement therapy (HRT). Remifemin® black cohosh extract
, the most extensively researched, non-prescription menopausal therapy, has been found to safely and effectively reduce hot flashes, night sweats and irritability.†
A new study by Nadia Obi, et al., “Herbal Preparation Use and Postmenopausal Breast Cancer,” has documented the safety of Remifemin for postmenopausal women with and without a history of breast cancer, who cannot take estrogen.†
The research, published in Cancer Epidemiol Biomarkers Prev (2009;18(8)August), supports earlier evidence of safety seen in Rebbeck’s study published in the International Journal of Cancer (2007, April 1, Volume 120, Issue 7, 1523-1528) and in Hirschberg’s study published in Menopause: The Journal of The North American Menopause Society (2007, Vol. 14, No. 1).
“With the trend among women seeking alternatives to HRT for the treatment of menopausal symptoms, it’s essential that their choices are proven to be safe,” said Dr. Belal Naser, Head of Drug Safety, Schaper & Brummer GmbH & Co KG, Salzgitter, Germany. “Hirschberg’s earlier study demonstrated that Remifemin does not promote endometrial thickening, increased breast density and breast cell proliferation, and is safe for women who should not take estrogen.” †
“In addition to safety, Obi’s study concluded that herbal medicines like Remifemin may exert a protective effect. The research showed a 26 percent improvement in breast health among women taking Remifemin.†
Lifestyle factors, including exercise and diet, had no effect on these results.” This “MARIE study” was supported by the German Cancer Aid (Deutsche Krebshilfe e.V.).
Remifemin is produced using a proprietary extraction method yielding the pure black cohosh root called RemiSure™ with a unique spectrum of active compounds. With 90 scientific papers and more than 15 published studies, Remifemin demonstrates consistent positive results.” For more information, visit www.remifemin.com